Study guide
5.3 PQA Threshold & Star Ratings Adherence Measures
PTCB Medication Therapy Management Certificate Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts & Format 1.2 Eligibility, Application & Testing 1.3 Pharmacy Technician Role in MTM 1.4 Domain Weights & Study Strategy
2 Chapter 2: Medication Product Knowledge
2.1 Strengths, Doses, and Drug Classes 2.2 Dosage Forms, Routes, and Administration Instructions 2.3 Storage, Special Handling, and Duration of Therapy 2.4 Interchangeable Classes and Forms for Cost Savings
3 Chapter 3: Terminology & History Collection
3.1 Patient-Friendly Medical Terminology 3.2 Medication Allergy vs Medication Intolerance 3.3 Adherence Definitions in Medication History 3.4 Medical History Components for MTM
4 Chapter 4: Medication-Related Problems & Labs
4.1 Common Medication-Related Problems Overview 4.2 Side Effects, Adverse Drug Reactions & Allergies in MTM 4.3 Nonadherence, Affordability Barriers & Gaps in Therapy 4.4 Lab Measures & Related Medical Terms in MTM
5 Chapter 5: Adherence Calculations
5.1 Days’ Supply, Quantity, and Dose 5.2 Proportion of Days Covered (PDC) 5.3 PQA Threshold & Star Ratings Adherence Measures
6 Chapter 6: Documentation Accuracy Reviews
6.1 Personal Medication Record (PMR) Accuracy Review 6.2 MAP and CMR Documentation Accuracy 6.3 MTM Billing Fields Accuracy Checks
7 Chapter 7: Prescribing Errors & Therapy Conflicts
7.1 Types of Prescribing Errors 7.2 Inappropriate Prescribing & Duplicate Therapy 7.3 Drug Interactions & Conflicting Therapies 7.4 Impact of Prescribing Errors & Medication Problems
8 Chapter 8: High-Risk Medications in Older Adults
8.1 2023 AGS Beers Criteria: High-Risk Medications in Older Adults 8.2 STOPP/START Concepts & Anticholinergic Burden in MTM Screening 8.3 High-Alert & Narrow Therapeutic Index Awareness for MTM Tech Support
9 Chapter 9: MTM Core Elements
9.1 Purpose of MTM & Five Core Elements 9.2 Medication Therapy Review (MTR) 9.3 Personal Medication Record (PMR) 9.4 Medication-Related Action Plan (MAP)
10 Chapter 10: Intervention, Documentation & CMS Rules
10.1 Intervention, Referral & Follow-Up 10.2 MTM Documentation Standards 10.3 CMS Part D MTM Targeting Requirements
11 Chapter 11: CMR, TMR, Billing & Workflow
11.1 Comprehensive Medication Review (CMR) 11.2 Targeted Medication Review (TMR) 11.3 CPT Billing Codes for MTM (99605 / 99606 / 99607) 11.4 Workflow Prioritization, Stages & Timelines
5.3 PQA Threshold & Star Ratings Adherence Measures
Key Takeaways Explain This Topic AI
PQA medication adherence measures generally define adherence as PDC ≥ 80% during the measurement period.
CMS Part D Star Ratings use PQA adherence measures for three chronic therapy areas: non-insulin diabetes medications, RAS antagonists, and statins.
RAS antagonists include ACE inhibitors, ARBs, and direct renin inhibitors used for the hypertension/heart-failure adherence measure construct.
Technicians support gap closure by identifying late refills, verifying days’ supply math, facilitating 90-day conversions when appropriate, scheduling outreach, and escalating barriers to the pharmacist.
Technicians do not independently change therapy; clinical interventions and counseling remain pharmacist/qualified-provider responsibilities.
Last updated: August 2026
5.3 PQA Threshold & Star Ratings Adherence Measures
Quick Answer: Under PQA adherence measures used in CMS Star Ratings , a patient is generally considered adherent when PDC ≥ 80% . The three Star adherence measures track non-insulin diabetes medications , RAS antagonists (ACE inhibitors, ARBs, direct renin inhibitors), and statins . Technicians close gaps by finding late fills, correcting DS math, enabling convenient fills, and escalating barriers—pharmacists handle clinical counseling and therapy changes.
Calculating PDC is not an academic exercise in MTM. Plans and pharmacies watch adherence because Medicare Part D Star Ratings include PQA-developed adherence measures. Better Stars support plan quality scores and competitiveness; for patients, higher PDC usually means fewer therapy gaps for chronic cardiovascular and diabetes care. Technicians who understand the 80% threshold and the three measure classes can prioritize outreach queues correctly.
The PQA ≥80% Rule
- Concept Detail
- Metric Proportion of Days Covered (PDC)
- Adherent threshold PDC ≥ 80%
- Below threshold Patient counts as nonadherent for the measure (gap)
- Why 80%? Widely used quality cut-point linking possession continuity to outcomes research and program policy
Numeric reminder: In a 180-day window, 80% requires about 144 covered days. In a 365-day window, about 292 covered days. When a gap report says “72% PDC,” you can translate that into roughly how many uncovered days remain—useful for pharmacist TMR prep.
Worked translation: PDC 72% over 365 days → covered days ≈ 0.72 × 365 ≈ 263 days . Shortfall vs 80% ≈ 292 − 263 = 29 days of additional coverage needed (about one on-time 30-day fill closing a month-long gap pattern), assuming the remaining year cooperates.
The Three Star Ratings Adherence Measures
CMS Part D Star Ratings include PQA adherence measures in three therapeutic areas:
Measure focus Typical drug examples Technician recognition cues
Diabetes (non-insulin) Metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, TZDs, some combination orals Chronic antihyperglycemics; insulin-only patients are generally handled differently in measure logic because insulin dosing is hard to capture from claims
RAS antagonists Lisinopril, enalapril ( ACEI ); losartan, valsartan ( ARB ); aliskiren ( DRI ) Blood pressure / heart-failure renin-angiotensin drugs
- Statins Atorvastatin, rosuvastatin, simvastatin, pravastatin Cholesterol / ASCVD risk reduction agents
- What is not one of the three Star adherence measures
Exam distractors often list opioids, antibiotics, PPIs, beta-blockers alone, or “all antihypertensives including amlodipine-only.” Remember the triad: diabetes (non-insulin), RAS antagonists, statins . Other PQA or Stars measures exist (for example, high-risk medications or CMR completion), but they are not these three adherence PDC measures.
RAS antagonists — quick class map
- Subclass Stem / cue Example
- ACE inhibitor -pril Lisinopril
- ARB -sartan Losartan
- Direct renin inhibitor Aliskiren Tekturna (brand recognition varies)
A patient on amlodipine alone is on a calcium channel blocker—not a RAS antagonist for this adherence measure. A patient on lisinopril plus amlodipine is in the RAS measure via the ACE inhibitor.
- Worked Gap Scenarios (Star-Relevant)
- Scenario A — Statin late fills
Mr. Chen’s atorvastatin history in a 180-day window: fills totaling 126 distinct covered days after overlap stacking.
PDC = 126 / 180 = 70% . Threshold fail (need 144 days). Technician actions: verify DS (confirm 1 tab daily → 30 tabs = 30 days), note fill dates 20+ days late, offer synchronized refill / 90-day discussion per protocol, schedule pharmacist adherence counseling.
Scenario B — Diabetes oral at the margin
Ms. Patel’s metformin ER: 148 covered days / 180 = 82.2% — passes. No panic outreach required for the threshold itself, but the technician still documents a recent 10-day late fill so the pharmacist can prevent a future slide below 80%.
Scenario C — RAS antagonist with BID math error upstream
Profile shows losartan 50 mg, quantity 60, billed as 60-day supply, directions 1 tab BID. Correct DS = 60 / 2 = 30 days . If PDC engines used the wrong 60-day DS, covered days are overstated. Technician recalculates, corrects documentation per workflow, and re-flags true gaps.
Scenario D — Multiple measures, one patient
A Medicare patient on metformin, lisinopril, and atorvastatin can appear on three adherence gap lists. Prioritize outreach that addresses shared barriers (cost, transportation, confusion) rather than three disconnected calls—coordinate with the pharmacist’s CMR/TMR plan.
How Technicians Support Gap Closure
Support action Why it helps Stars/PDC Boundary
Pull and triage gap lists Focuses limited CMR/TMR time on patients below 80% Do not hide patients to “protect” scores
Recalculate DS and refill timing Fixes false gaps and true gaps rooted in bad math Escalate unclear regimens
Educate on auto-refill / med sync / 90-day fills (approved scripts) Reduces logistical gaps No unauthorized therapy changes
Identify cost, side-effect, or literacy barriers Surfaces root causes Pharmacist counsels clinically
Schedule follow-up and document outreach attempts Improves closure rates and audit trail Do not invent successful CMR notes
Flag duplicates or wrong drugs on the list Prevents chasing the wrong therapy Pharmacist confirms measure eligibility
Realistic technician script pattern (logistics, not clinical advice)
“I see your cholesterol medication refill was about three weeks later than expected. I can help check mail-order or a 90-day option and set a time for you to speak with the pharmacist about any problems taking it.” That language supports gap closure without diagnosing or altering therapy.
Connecting Chapters: Math → Quality → MTM Workflow
Section 5.1 ensures quantity, dose, and days’ supply are correct.
Section 5.2 turns fills into PDC.
Section 5.3 applies the ≥80% cut and the diabetes / RAS / statin Star triad so you know which chronic meds drive adherence work queues.
Later chapters on documentation accuracy, TMRs, and CMR completion sit beside this work: adherence flags often trigger Targeted Medication Reviews , and CMR completion is its own Star-related process measure. For this section, keep the focus on PQA PDC ≥ 80% and technician-powered gap closure within scope.
Quick self-check
Can you state the threshold without hesitation? ≥80% PDC .
Can you name the three Star adherence classes? Non-insulin diabetes, RAS antagonists, statins .
Can you convert a percent into covered-day shortfall for a known window?
Can you list three technician actions that improve adherence logistics without practicing pharmacy independently?
If yes, you are ready for Domain 2 calculation items that blend arithmetic with quality-measure literacy.